Publication: Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices
Issued Date
2020-11-01
Resource Type
ISSN
1536481X
10570829
10570829
Other identifier(s)
2-s2.0-85095977472
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Glaucoma. Vol.29, No.11 (2020), 1065-1069
Suggested Citation
Naris Kitnarong, Benjawan Srikulsasitorn, Tanakorn Aurboonsong Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices. Journal of Glaucoma. Vol.29, No.11 (2020), 1065-1069. doi:10.1097/IJG.0000000000001610 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60563
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Glycerin-preserved Human-donor Corneoscleral Patch Grafts for Glaucoma Drainage Devices
Other Contributor(s)
Abstract
© 2020 Wolters Kluwer Health, Inc. All rights reserved. Precis:Glycerin-preserved, human-donor, corneoscleral patch grafts are effective and safe for glaucoma drainage device (GDD) implantation, and they are comparable to previously reported materials. It can be preserved with the sterile technique for up to 12 months.Purpose:To evaluate the efficacy and safety of glycerin-preserved human donor corneoscleral tissue as the patch graft for GDD implantation.Patients and Methods:This was a retrospective noncomparative study from the medical records of 102 eyes from 102 glaucoma patients who underwent GDD implantation by or under supervision of a single surgeon (N.K.) at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand between January 2006 and December 2016. The glycerin-preserved human-donor corneoscleral tissue was used as the patch graft to cover the tube portion of GDD over the sclera. The primary outcome measure was the occurrence of patch graft-related complications.Results:There were 64 males and 38 females with the mean age of 52.8±18.5 years. The underlying diseases included failed filtration surgery with primary open-angle glaucoma 32 eyes and primary angle-closure glaucoma 15 eyes, congenital glaucoma 3 eyes and secondary glaucoma 52 eyes. The mean of ocular surgeries before GDD implantation was 2.3±1.1. Patch graft-related complications included tube exposure in 4 eyes (3.9%) and wound leakage in 4 eyes (3.9%). Eyes with tube exposure underwent regrafting 3 eyes and tube reposition 1 eye. Eyes with wound leaking resolved spontaneously 2 eyes and underwent conjunctival resuturing 2 eyes. The 5-year survival rate of the corneoscleral graft was 95.7%. There was no recurrence of graft-related complications after surgical procedure to correct the complications. Postoperatively, the mean of intraocular pressure and antiglaucoma medications decreased significantly from 27.4±9.8 mm Hg and 3.8±0.93 to 13.8±6.4 mm Hg (P<0.001) and 1.6±1.5 (P<0.001) at the last visit, respectively. The mean follow-up time was 59.9 months (range, 1 to 144.7 mo).Conclusion:The glycerin-preserved human-donor corneoscleral tissue using as the patch graft was a safe alternative for GDD tube coverage. The patch graft-related complications was comparable to other materials.